Conferences
[1] Sun S, Wu J, Chen R, et al.
SARS-CoV-2 Omicron variant: viral spread dynamics, disease burden, and
vaccine effectiveness[J]. Curr Med (Cham), 2022, 1(1): 14.
[2] Kiss Z, Wittmann I, Polivka L,
et al. Nationwide Effectiveness of First and Second SARS-CoV2 Booster
Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE
2 Study)[J]. Front Immunol, 2022, 13: 905585.
[3] Li D, Li A E, Li Z Q, et al.
SARS-CoV-2 Delta Variant in Jingmen City, Hubei Province, China, 2021:
Children Susceptible and Vaccination Breakthrough Infection[J].
Front Microbiol, 2022, 13: 856757.
[4] Tan S H X, Cook A R, Heng D,
et al. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5
to 11 Years of Age[J]. N Engl J Med, 2022, 387(6): 525-532.
[5] Zhang X, Zhang H, He X.
SARS-CoV-2 Omicron: a new challenge for pandemic and vaccine[J].
Signal Transduct Target Ther, 2022, 7(1): 211.
[6] Andreano E, Paciello I,
Marchese S, et al. Anatomy of Omicron BA.1 and BA.2 neutralizing
antibodies in COVID-19 mRNA vaccinees[J]. Nat Commun, 2022, 13(1):
3375.
[7] Li J, Song R, Yuan Z, et al.
Protective Effect of Inactivated COVID-19 Vaccines against Progression
of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in
Beijing, China, in 2022[J]. Vaccines (Basel), 2022, 10(8).
[8] Gu H, Krishnan P, Ng D Y M, et
al. Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine
Hotel, Hong Kong, China, November 2021[J]. Emerg Infect Dis, 2022,
28(2): 460-462.
[9] Hua Q, Zheng D, Yu B, et al.
Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused
by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort
Study[J]. Vaccines (Basel), 2022, 10(10).
[10] Wu D, Zhang Y, Tang L, et
al. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic,
Pneumonia, and Severe Disease Caused by the Delta Variant: Real World
Study and Evidence - China, 2021[J]. China CDC Wkly, 2022, 4(4):
57-65.
[11] Ma C, Sun W, Tang T, et al.
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19
vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe
COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an
outbreak in Yunnan, China, 2021[J]. Vaccine, 2022, 40(20):
2869-2874.
[12] Liu B, Gidding H, Stepien S,
et al. Relative effectiveness of COVID-19 vaccination with 3 compared to
2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian
population with low prior rates of SARS-CoV-2 infection[J]. Vaccine,
2022, 40(43): 6288-6294.
[13] Nittayasoot N, Thammawijaya
P, Tharmaphornpilas P, et al. Rapid method through routine data to
evaluate real-world vaccine effectiveness against coronavirus disease
2019 (COVID-19) infection: lessons from Thailand[J]. Health Res
Policy Syst, 2022, 20(1): 29.
[14] Tseng H F, Ackerson B K, Luo
Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and
Delta variants[J]. Nat Med, 2022, 28(5): 1063-1071.
[15] Tang P, Hasan M R,
Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine
effectiveness against the SARS-CoV-2 Delta variant in Qatar[J]. Nat
Med, 2021, 27(12): 2136-2143.
[16] Hu Z, Tao B, Li Z, et al.
Effectiveness of inactivated COVID-19 vaccines against severe illness in
B.1.617.2 (Delta) variant-infected patients in Jiangsu, China[J].
Int J Infect Dis, 2022, 116: 204-209.
[17] Hara M, Furue T, Fukuoka M,
et al. Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan:
A Case-Control Study[J]. Vaccines (Basel), 2022, 10(5).
[18] Kherabi Y, Launay O, Luong
Nguyen L B. COVID-19 Vaccines against Omicron Variant: Real-World Data
on Effectiveness[J]. Viruses, 2022, 14(10).
[19] Kang M, Yi Y, Li Y, et al.
Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by
the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A
Cohort Study[J]. Ann Intern Med, 2022, 175(4): 533-540.
[20] Fu Y, Zhao J, Wei X, et al.
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address
COVID-19 Pandemic in China: Evidence From Randomized Control Trials and
Real-World Studies[J]. Front Public Health, 2022, 10: 917732.
[21] Li X N, Huang Y, Wang W, et
al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta
variant infection in Guangzhou: a test-negative case-control real-world
study[J]. Emerg Microbes Infect, 2021, 10(1): 1751-1759.
[22] Huang Z, Xu S, Liu J, et al.
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against
SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and
death[J]. BMC Med, 2022, 20(1): 400.
[23] Bai W, Sha S, Cheung T, et
al. Optimizing the dynamic zero-COVID policy in China[J]. Int J Biol
Sci, 2022, 18(14): 5314-5316.
[24] Qin W, Zhang X, Wang Y, et
al. The acceptance to heterologous booster vaccination of COVID-19
vaccine among HCWs and targeted population: A cross-sectional study in
central China[J]. Front Public Health, 2022, 10: 943876.
[25] Yin Z, Wen T, Fang Q, et al.
Assessment of mumps-containing vaccine effectiveness by dose during 2006
to 2020 in Quzhou, China[J]. Hum Vaccin Immunother, 2022, 18(5):
2086774.
[26] Yin Y, Lin J, Yuan S, et al.
A booster shot of vaccine against SARS-CoV-2 should be rigorously
promoted and implemented in China[J]. J Infect, 2022.
[27] Zhang Y, Belayachi J, Yang
Y, et al. Real-world study of the effectiveness of BBIBP-CorV
(Sinopharm) COVID-19 vaccine in the Kingdom of Morocco[J]. BMC
Public Health, 2022, 22(1): 1584.
[28] Adams K, Rhoads J P, Surie
D, et al. Vaccine Effectiveness of Primary Series and Booster Doses
against Omicron Variant COVID-19-Associated Hospitalization in the
United States[J]. medRxiv, 2022.
[29] Kong W, Zhong Q, Chen M, et
al. Ad5-nCoV booster and Omicron variant breakthrough infection
following two doses of inactivated vaccine elicit comparable antibody
levels against Omicron variants[J]. J Med Virol, 2022.
[30] Wolter N, Jassat W, Walaza
S, et al. Early assessment of the clinical severity of the SARS-CoV-2
omicron variant in South Africa: a data linkage study[J]. Lancet,
2022, 399(10323): 437-446.
[31] Garrett N, Tapley A,
Andriesen J, et al. High Asymptomatic Carriage With the Omicron Variant
in South Africa[J]. Clin Infect Dis, 2022, 75(1): e289-e292.
[32] Sharma R P, Gautam S, Sharma
P, et al. Genomic profile of SARS-CoV-2 Omicron variant and its
correlation with disease severity in Rajasthan[J]. Front Med
(Lausanne), 2022, 9: 888408.
[33] Petersen M S, S Í K, Eliasen
E H, et al. Clinical characteristics of the Omicron variant - results
from a Nationwide Symptoms Survey in the Faroe Islands[J]. Int J
Infect Dis, 2022, 122: 636-643.
[34] Raju M K, Vivian Thangaraj J
W, Selvavinayagam T S, et al. Clinical profile of patients infected with
suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India,
December 2021-January 2022[J]. Indian J Med Res, 2022, 155(1):
165-170.
[35] Chemaitelly H, Tang P, Hasan
M R, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2
Infection in Qatar[J]. N Engl J Med, 2021, 385(24): e83.
[36] Richardson V L, Camacho
Franco M A, Bautista Márquez A, et al. Vaccine Effectiveness of CanSino
(Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare
Workers-Mexico, March-December 2021[J]. Clin Infect Dis, 2022,
75(Supplement_2): S167-s173.
[37] Yang B, Wong I O L, Xiao J,
et al. Effectiveness of CoronaVac and BNT162b2 Vaccines Against Severe
Acute Respiratory Syndrome Coronavirus 2 Omicron BA.2 Infections in Hong
Kong[J]. The Journal of Infectious Diseases, 2022: jiac360.
[38] Mcmenamin M E, Nealon J, Lin
Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2
and CoronaVac against COVID-19 in Hong Kong: a population-based
observational study[J]. Lancet Infect Dis, 2022, 22(10): 1435-1443.
[39] Brosh-Nissimov T, Hussein K,
Wiener-Well Y, et al. Hospitalized patients with severe COVID-19 during
the Omicron wave in Israel - benefits of a fourth vaccine dose[J].
Clin Infect Dis, 2022.
[40] Andrews N, Stowe J, Kirsebom
F, et al. Effectiveness of COVID-19 booster vaccines against
COVID-19-related symptoms, hospitalization and death in England[J].
Nat Med, 2022, 28(4): 831-837.
[41] Acuti Martellucci C, Flacco
M E, Soldato G, et al. Effectiveness of COVID-19 Vaccines in the General
Population of an Italian Region before and during the Omicron
Wave[J]. Vaccines (Basel), 2022, 10(5).
[42] Miyauchi S, Hiyama T, Nakano
Y, et al. Real-World Effectiveness of a Booster Dose of the COVID-19
Vaccines among Japanese University Students[J]. Vaccines (Basel),
2022, 10(8).
[43] Jin P, Guo X, Chen W, et al.
Safety and immunogenicity of heterologous boost immunization with an
adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine
(Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled
trial[J]. PLoS Med, 2022, 19(5): e1003953.
[44] Zhu F C, Guan X H, Li Y H,
et al. Immunogenicity and safety of a recombinant adenovirus
type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or
older: a randomised, double-blind, placebo-controlled, phase 2
trial[J]. Lancet, 2020, 396(10249): 479-488.
[45] Xu K, Fan C, Han Y, et al.
Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of
data published by 31 December 2021[J]. Int Immunol, 2022.
[46] Li J, Hou L, Guo X, et al.
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac
vaccination: a randomized phase 4 trial[J]. Nat Med, 2022, 28(2):
401-409.
[47] Li J X, Wu S P, Guo X L, et
al. Safety and immunogenicity of heterologous boost immunisation with an
orally administered aerosolised Ad5-nCoV after two-dose priming with an
inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised,
open-label, single-centre trial[J]. Lancet Respir Med, 2022, 10(8):
739-748.
[48] Li Z P, Shi Y F, Hou L H, et
al. Batch-to-batch consistency trial of an adenovirus type-5
vector-based COVID-19 vaccine in adults aged 18 years and above[J].
Expert Rev Vaccines, 2022.